Cowen cut shares of Axovant Sciences (NASDAQ:AXON) from an outperform rating to a market perform rating in a research note issued to investors on Friday.

A number of other equities analysts also recently commented on the company. BidaskClub downgraded Axovant Sciences from a sell rating to a strong sell rating in a report on Friday, September 15th. Zacks Investment Research upgraded Axovant Sciences from a hold rating to a strong-buy rating and set a $8.00 price objective on the stock in a report on Monday, October 9th. HC Wainwright restated a buy rating on shares of Axovant Sciences in a report on Thursday, October 19th. Chardan Capital restated a sell rating and issued a $3.00 price objective on shares of Axovant Sciences in a report on Saturday, September 23rd. Finally, Oppenheimer restated a buy rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $14.14.

Axovant Sciences (NASDAQ:AXON) opened at $2.09 on Friday. The firm has a market capitalization of $225.11, a PE ratio of -0.91 and a beta of 0.06. Axovant Sciences has a twelve month low of $2.06 and a twelve month high of $27.98. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34.

Axovant Sciences (NASDAQ:AXON) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). sell-side analysts forecast that Axovant Sciences will post -2.17 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in AXON. FMR LLC boosted its position in Axovant Sciences by 968.5% during the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares during the period. Janus Henderson Group PLC bought a new stake in Axovant Sciences during the second quarter worth approximately $47,854,000. OxFORD Asset Management LLP boosted its position in Axovant Sciences by 842.1% during the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the period. Capital Research Global Investors boosted its position in Axovant Sciences by 21.8% during the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after purchasing an additional 619,226 shares during the period. Finally, Eagle Asset Management Inc. bought a new stake in Axovant Sciences during the third quarter worth approximately $4,471,000. 96.93% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/01/16/axovant-sciences-axon-cut-to-market-perform-at-cowen.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.